Bang-jiang Fang

Prof. Dr. Bang-jiang Fang


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Phytomedicine
Verified
Journal Article
Closed access
SZShuang Zhou
Shuang Zhou
JFJun Feng
Jun Feng
QXQin Xie
Qin Xie
THTingrong Huang
Tingrong Huang
XXXiaoming Xu
Xiaoming Xu
BFBang-jiang Fang
Bang-jiang Fang

30 June 2020 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
GCGang Chen
Gang Chen
KXKailiang Xu
Kailiang Xu
FSFangyuan Sun
Fangyuan Sun
YSYuxia Sun
Yuxia Sun
ZKZiyuan Kong
Ziyuan Kong
BFBang-jiang Fang
Bang-jiang Fang
Background. Multidrug-resistant (MDR) bacteria are the main cause of lower respiratory tract infections (LRTIs) with high mortality. The purpose of this study is to identify the risk factors associated with MDR by performing a systematic review and meta-analysis.Methods. PubMed, EMBASE (via Ovid), and Cochrane Library were systematically searched for studies on the risk factors for MDR bacteria in LRTIs as of November 30, 2019. Literature screening, data abstraction, and quality assessment of the eligible studies were performed independently by two researchers.Results. A total of 3,607 articles were retrieved, of which 21 articles representing 20 cohort studies published in English were included after title/abstract and full-text screening. Among the 21 articles involving 7,650 patients and 1,360 MDR organisms, ten reported the risk factors for MDR Gram-positive bacteria (GPB) and Gram-negative bacteria (GNB), ten for MDR GNB, and one for MDR GPB. The meta-analysis results suggested that prior antibiotic treatment, inappropriate antibiotic therapy, chronic lung disease, chronic liver disease and cerebral disease, prior MDR and PA infection/colonization, recent hospitalization, longer hospitalization stay, endotracheal tracheostomy and mechanical ventilation, tube feeding, nursing home residence, and higher disease severity score were independent risk factors for MDR bacteria.Conclusions. This review identified fourteen clinical factors that might increase the risk of MDR bacteria in patients with LRTIs. Clinicians could take into account these factors when selecting antibiotics for patients and determine whether coverage for MDR bacteria is required. More well-designed studies are needed to confirm the various risk factors for MDR bacteria in the future.

26 June 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JLJiamin Lu
Jiamin Lu
WZWen Zhang
Wen Zhang
YHYuzhou He
Yuzhou He
MJMei Jiang
Mei Jiang
ZLZhankui Liu
Zhankui Liu
CWChuanqi Wan
Chuanqi Wan
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, and its pathogenesis involves complex interactions between the host and the microbiome. The integration of multi-omics has important value in revealing the mechanism of host-microbiome interaction. It is a key tool for promoting accurate diagnosis and guiding dynamic treatment strategies in sepsis. However, multi-omics data integration faces technical challenges, such as data heterogeneity and platform variability, as well as analytical hurdles, such as the “curse of dimensionality.” Fortunately, researchers have developed two integration strategies: data-driven and knowledge-guided approaches, which employ various dimensionality reduction techniques and integration methods to handle multi-omics datasets. This review discusses the applications of multi-omics technologies in host-microbiome interactions in sepsis, highlighting their potential in identifying novel diagnostic biomarkers and developing personalized and dynamic treatment strategies. It also summarizes commonly used systems biology resources and computational tools for data integration; the review outlines the challenges in this field and proposes potential directions for future studies.

30 August 2023 in Heliyon
Verified
Journal Article
Open access
CLChangya Liu
Changya Liu
XWXinxin Wu
Xinxin Wu
RDRou Deng
Rou Deng
XXXiangru Xu
Xiangru Xu
CCCaiyu Chen
Caiyu Chen
BFBang-jiang Fang
Bang-jiang Fang
To evaluate the prognostic ability of systemic immune-inflammation index (SII) combine with quick Sequential Organ Failure Assessment (qSOFA) criteria in predicting the 28-day mortality of sepsis. A retrospective cohort study was conducted, with the population comprised in whom sepsis was confirmed. Clinical and laboratory data recorded were analyzed. The score of Sequential Organ Failure Assessment (SOFA), SII, qSOFA were calculated. Multivariable regression, receiver operating characteristic (ROC) analysis and Kaplan-Meier method were used to identify and compared the predictors of prognosis among SOFA, qSOFA, and the combination of SII with qSOFA. A total of 349 patients admitted from December 2020 and December 2022 were included in the cohort. 95 (27.2%) of whom had died by day 28. The SII, SOFA, and qSOFA scores were significant higher in the non-survivors than that of survivors (P < 0.05), and identified as independent predictors of sepsis mortality. The addition of SII to qSOFA shown an area under receiver operator characteristic (AUROC) of 0.840 (95% CI: 0.787–0.884), manifested an effective ability in predicting poor outcome than other scoring systems. The optimum cutoff for SII (>1.7668) and qSOFA (>1) represented a high risk level in 28-day mortality of sepsis, were performed and identified in Kaplan-Meier survival curves (log-rank test, HR: 6.942, 95% CI: 3.976–12.121; P < 0.0001). The SII in addition to qSOFA provided an effective prognostic tool for predicting mortality in sepsis.

11 October 2021 in Journal of Evidence-Based Medicine
Verified
Journal Article
Open access
PDF file
LGLong Ge
Long Ge
HZHongfei Zhu
Hongfei Zhu
QWQi Wang
Qi Wang
MLMengting Li
Mengting Li
JCJianxiong Cai
Jianxiong Cai
DWDarong Wu
Darong Wu
Background: The coronavirus disease 2019 (COVID‐19) has turned into a pandemic and resulted in huge death tolls and burdens. Integrating Chinese and western medicine has played an important role in the fight against the COVID‐19 pandemic.Purpose: We aimed to develop a living evidence‐based guideline of integrating Chinese and western medicine for COVID‐19.Study design: Living evidence‐based guideline.Methods: This living guideline was developed using internationally recognized and accepted guideline standards, dynamically monitoring the release of new clinical evidence, and quickly updating the linked living systematic review, evidence summary tables, and recommendations. Modified Delphi method was used to reach consensus for all recommendations. The certainty of the evidence, resources, and other factors were fully considered, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to rate the certainty of evidence and the strength of recommendations.Results: The first version of this living guidance focuses on patients who are mild or moderate COVID‐19. A multidisciplinary guideline development panel was established. Ten clinical questions were identified based on the status of evidence and a face‐to‐face experts’ consensus. Finally, nine recommendations were reached consensus, and were formulated from systematic reviews of the benefits and harms, certainty of evidence, public accessibility, policy supports, feedback on proposed recommendations from multidisciplinary experts, and consensus meetings.Conclusion: This guideline panel made nine recommendations, which covered five traditional Chinese medicine (TCM) prescription granules/decoction (MXXFJD, QFPD, XFBD, TJQW, and JWDY), three Chinese patent medicines (LHQW granules/capsule, JHQG granules, and LHQK granules), and one Chinese herbal injection (XBJ injection). Of them, two were strongly recommended (LHQW granules/capsule and QFPD decoction), and five were weakly recommended (MXXFJD decoction, XFBD decoction, JHQG granules, TJQW granules, and JWDY decoction) for the treatment of mild and moderate COVID‐19; two were weakly recommended against (XBJ injection and LHQK granules) the treatment of mild and moderate COVID‐19. The users of this living guideline are most likely to be clinicians, patients, governments, ministries, and health administrators.

8 March 2023 in Cell Proliferation
Verified
Journal Article
Open access
JSJianlin Shen
Jianlin Shen
XLXiaoning Lin
Xiaoning Lin
FDFeifei Dai
Feifei Dai
GCGuoli Chen
Guoli Chen
HLHaibin Lin
Haibin Lin
HLHuan Liu
Huan Liu
Osteoporosis is an ageing‐related disease, that has become a major public health problem and its pathogenesis has not yet been fully elucidated. Substantial evidence suggests a strong link between overall age‐related disease progression and epigenetic modifications throughout the life cycle. As an important epigenetic modification, ubiquitination is extensively involved in various physiological processes, and its role in bone metabolism has attracted increasing attention. Ubiquitination can be reversed by deubiquitinases, which counteract protein ubiquitination degradation. As the largest and most structurally diverse cysteinase family of deubiquitinating enzymes, ubiquitin‐specific proteases (USPs), comprising the largest and most structurally diverse cysteine kinase family of deubiquitinating enzymes, have been found to be important players in maintaining the balance between bone formation and resorption. The aim of this review is to explore recent findings highlighting the regulatory functions of USPs in bone metabolism and provide insight into the molecular mechanisms governing their actions during bone loss. An in‐deep understanding of USPs‐mediated regulation of bone formation and bone resorption will provide a scientific rationale for the discovery and development of novel USP‐targeted therapeutic strategies for osteoporosis.